SLIT2 and neoplasm: Srivastava et al. showed that the EPHA2 TKI ensartinib may synergistically act with the roundabout guidance receptor 1 (ROBO1) ligand slit guidance ligand 2 (SLIT2) to attenuate the growth of squamous LC cells, which exercises its tumor-suppressive effect by either EPHA2 heterodimerizing or homodimer binding and inhibits AKT activity [61].